Recently, the innovative product Transcatheter Mitral Valve Clamp System of Hangzhou Valgen Medtech Co., Ltd. was approved for marketing by China NMPA.

　　This product consists of two components: a guide sheath and a mitral valve clamp system. Among them, the mitral valve clamp system includes a mitral valve clamp and a delivery system. The elastic center sealing network structure of the mitral valve clamp can increase the clamping and sealing performance, reduce residual reflux at the center, and reduce the clamping force of valve leaflets. At the same time, the mitral valve clamp also has functions such as individual capture of valve leaflets and repeated positioning capture, which can improve operational accuracy and reduce the risk of mitral valve clamp detachment and valve leaflet perforation.

　　This product is suitable for patients who are having a high risk surgical intervention upon assessment of cardiac team, and who have are a suitable anatomical structure of the mitral valve for degenerative mitral regurgitation (MR ≥ 3+) . The marketing this product will provide more options for clinical treatment.

　　The NMPA will strengthen the post-marketing surveillance of the product to protect the safety of medical devices used by patients.